Cancer stem-like cell characteristics induced by EB virus-encoded LMP1 contribute to radioresistance in nasopharyngeal carcinoma by suppressing the p53-mediated apoptosis pathway

Cancer Letters

Volumn 344, Issue 2, 2014, Pages 260-271

  Yang, Chang Fu ^b   Peng, Li Xia ^a   Huang, Tie Jun ^c   Yang, Guang Da ^a   Chu, Qiao Qiao ^d   Liang, Ying Ying ^a   Cao, Xue ^a   Xie, Ping ^a   Zheng, Li Sheng ^a   Huang, Hong Bing ^a   Cai, Mao De ^b   Huang, Jia Ling ^e   Liu, Ran Yi ^a   Zhu, Zhen Yu ^f   Qian, Chao Nan ^a   Huang, Bi Jun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c SECOND PEOPLE S HOSPITAL OF SHENZHEN   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cancer stem cells (CSCs); Epstein Barr virus (EBV); Latent membrane protein 1 (LMP1); Nasopharyngeal carcinoma (NPC); P53 signalling pathway; Radioresistance

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; HERMES ANTIGEN; LATENT MEMBRANE PROTEIN 1; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER STEM CELL; CARCINOMA CELL; CELL COUNT; CELL GROWTH; CELL RENEWAL; CELL SELECTION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; IMMUNOFLUORESCENCE MICROSCOPY; IN VIVO STUDY; MOLECULAR MECHANICS; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VECTOR CONTROL;

HUMAN HERPESVIRUS 4;

CANCER STEM CELLS (CSCS); EPSTEIN-BARR VIRUS (EBV); LATENT MEMBRANE PROTEIN 1 (LMP1); NASOPHARYNGEAL CARCINOMA (NPC); P53 SIGNALLING PATHWAY; RADIORESISTANCE;

ANIMALS; APOPTOSIS; HERPESVIRUS 4, HUMAN; HUMANS; INFRARED RAYS; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; VIRAL MATRIX PROTEINS;

EID: 84893655345     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.11.006     Document Type: Article

References (38)

1. Pagano J.S. Epstein-Barr virus: the first human tumor virus and its role in cancer. Proc. Assoc. Am. Phys. 1999, 111:573-580.
2. Chan A.T., Lo Y.M., Zee B., Chan L.Y., Ma B.B., Leung S.F., Mo F., Lai M., Ho S., Huang D.P., Johnson P.J. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J. Natl. Cancer Inst. 2002, 94:1614-1619.
3. Wang H.Y., Sun B.Y., Zhu Z.H., Chang E.T., To K.F., Hwang J.S., Jiang H., Kam M.K., Chen G., Cheah S.L., Lee M., Liu Z.W., Chen J., Zhang J.X., Zhang H.Z., He J.H., Chen F.L., Zhu X.D., Huang M.Y., Liao D.Z., Fu J., Shao Q., Cai M.B., Du Z.M., Yan L.X., Hu C.F., Ng H.K., Wee J.T., Qian C.N., Liu Q., Ernberg I., Ye W., Adami H.O., Chan A.T., Zeng Y.X. Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival. J. Clin. Oncol. 2011, 29:4516-4525.
4. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
5. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
6. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
7. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Natl. Acad. Sci. USA 2003, 100:3983-3988.
8. Takaishi S., Okumura T., Tu S., Wang S.S., Shibata W., Vigneshwaran R., Gordon S.A., Shimada Y., Wang T.C. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27:1006-1020.
9. Prince M.E., Sivanandan R., Kaczorowski A., Wolf G.T., Kaplan M.J., Dalerba P., Weissman I.L., Clarke M.F., Ailles L.E. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. 2007, 104:973-978.
10. Patrawala L., Calhoun T., Schneider-Broussard R., Li H., Bhatia B., Tang S., Reilly J.G., Chandra D., Zhou J., Claypool K., Coghlan L., Tang D.G. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25:1696-1708.
11. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancerstem cells. Cancer Res. 2007, 67:1030-1037.
12. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., Shelton A.A., Parmiani G., Castelli C., Clarke M.F. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104:10158-10163.
13. Kondo S., Wakisaka N., Muramatsu M., Zen Y., Endo K., Murono S., Sugimoto H., Yamaoka S., Pagano J.S., Yoshizaki T. Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines. J. Virol. 2011, 85:11255-11264.
14. Brunner T.B., Kunz-Schughart L.A., Grosse-Gehling P., Baumann M. Cancer stem cells as a predictive factor in radiotherapy. Semin. Radiat. Oncol. 2012, 22:151-174.
15. Squatrito M., Brennan C.W., Helmy K., Huse J.T., Petrini J.H., Holland E.C. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 2010, 18:619-629.
16. Austen B., Skowronska A., Baker C., Powell J.E., Gardiner A., Oscier D., Majid A., Dyer M., Siebert R., Taylor A.M., Moss P.A., Stankovic T. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J. Clin. Oncol. 2007, 25:5448-5457.
17. Yin H., Glass J. The phenotypic radiation resistance of CD44+/CD24-or low breast cancer cells is mediated through the enhanced activation of ATM signaling. Plos One 2011, 6:e24080.
18. Bose S., Yap L.F., Fung M., Starzcynski J., Saleh A., Morgan S., Dawson C., Chukwuma M.B., Maina E., Buettner M., Wei W., Arrand J., Lim P.V., Young L.S., Teo S.H., Stankovic T., Woodman C.B., Murray P.G. The ATM tumour suppressor gene is down-regulated in EBV-associated nasopharyngeal carcinoma. J. Pathol. 2009, 217:345-352.
19. Liu M.T., Chen Y.R., Chen S.C., Hu C.Y., Lin C.S., Chang Y.T., Wang W.B., Chen J.Y. Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene 2004, 23:2531-2539.
20. Liu M.T., Chang Y.T., Chen S.C., Chuang Y.C., Chen Y.R., Lin C.S., Chen J.Y. Epstein-Barr virus latent membrane protein 1 represses p53-mediated DNA repair and transcriptional activity. Oncogene 2005, 24:2635-2646.
21. Selbo P.K., Weyergang A., Eng M.S., Bostad M., Mælandsmo G.M., Høgset A., Berg K. Strongly amphiphilic photosensitizers are not substrates of the cancer stem cell marker ABCG2 and provides specific and efficient light-triggered drug delivery of an EGFR-targeted cytotoxic drμg. J. Control Release 2012, 159:197-203.
22. Zhang L., Hu J.J., Gong F. MG132 inhibition of proteasome blocks apoptosis induced by severe DNA damage. Cell Cycle 2011, 10:3515-3518.
23. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
24. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 2008, 8:545-554.
25. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
26. Xie G., Zhan J., Tian Y., Liu Y., Chen Z., Ren C., Sun Q., Lian J., Chen L., Ruan J., Ye C., Sun A., Yuan Y. Mammosphere cells from high-passage MCF7 cell line show variable loss of tumorigenicity and radioresistance. Cancer Lett. 2012, 316:53-61.
27. Baumann M., Krause M. CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy. Clin. Cancer Res. 2010, 16:5091-5093.
28. Bernstein C., Bernstein H., Payne C.M., Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat. Res. 2002, 511:145-178.
29. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., Takaoka M., Nakagawa H., Tort F., Fugger K., Johansson F., Sehested M., Andersen C.L., Dyrskjot L., Ørntoft T., Lukas J., Kittas C., Helleday T., Halazonetis T.D., Bartek J., Gorgoulis V.G. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
30. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio R.A., Kastrinakis N.G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., Halazonetis T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
31. Gruhne B., Sompallae R., Masucci M.G. Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene 2009, 28:3997-4008.
32. Gudkov A.V., Komarova E.A. The role of p53 in determining sensitivity to radiotherapy. Nat. Rev. Cancer 2003, 3:117-129.
33. Takai H., Naka K., Okada Y., Watanabe M., Harada N., Saito S., Anderson C.W., Appella E., Nakanishi M., Suzuki H., Nagashima K., Sawa H., Ikeda K., Motoyama N. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J. 2002, 21:5195-5205.
34. Sun Y., Hegamyer G., Cheng Y.J., Hildesheim A., Chen J.Y., Chen I.H., Cao Y., Yao K.T., Colburn N.H. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. USA 1992, 89:6516-6520.
35. Spruck C.H., Tsai Y.C., Huang D.P., Yang A.S., Rideout W.M., Gonzalez-Zulueta M., Choi P., Lo K.W., Yu M.C., Jones P.A. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res. 1992, 52:4787-4790.
36. Chen L., Gilkes D.M., Pan Y., Lane W.S., Chen J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 2005, 24:3411-3422.
37. Yap D.B., Hsieh J.K., Lu X. Mdm2 inhibits the apoptotic function of p53 mainly by targeting it for degradation. J. Biol. Chem. 2000, 275:30242-37296.
38. Cheng Q., Chen J. Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle 2010, 9:472-478.